Thera-SAbDab

DARATUMUMAB

>   Structural Summary
TherapeuticDaratumumab
TargetCD38
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK
100% seqID Fv Structure7dha [Fvs: CB], 7dun [Fvs: HL], 7duo [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Active
Recorded Developmental TechnologyMedarex HuMAb Mouse
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedBoston Medical Center, Bristol-Myers Squibb, Dana-Farber Cancer Institute, French Innovative Leukemia Organisation, Genentech, Genmab, Janssen Biotech, Janssen Research & Development, M. D. Anderson Cancer Center, Syros Pharmaceuticals
Conditions ApprovedMultiple myeloma
Conditions ActiveAmyloid light-chain amyloidosis, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Myelodysplastic syndromes, Precursor B-cell lymphoblastic leukaemia-lymphoma, Precursor T-cell lymphoblastic leukaemia-lymphoma, Prostate cancer, T-cell lymphoma, Waldenstrom's macroglobulinaemia, Solid tumours
Conditions DiscontinuedNon-small cell lung cancer
Notes

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy